Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,403.05
(
-0.07%
)
US TECH 100
28,134.00
(
-0.36%
)
Dow Jones
49,686.12
(
0.32%
)
Brent Oil
107.42
(
0.62%
)
Bitcoin
76,891.45
(
-0.10%
)
News Focus
News Focus
Post# of 257581
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122989
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 239340

Friday, 10/15/2021 3:58:06 PM

Friday, October 15, 2021 3:58:06 PM

Post# of 257581
CHMP approves PFE’s Abrocitinib for_moderate/severe atopic dermatitis:

https://finance.yahoo.com/news/pfizer-abrocitinib-receives-positive-chmp-115000136.html

Abrocitinib is already approved for atopic dermatitis in Japan, and now it will be approved in the EU following rubber-stamping by the EU Commission in a couple of months. It figures to be a needle-moving drug even for a company as large as PFE. Abrocitinib is a pill that has better efficacy than market-leading (injectable) Dupixent from SNY/REGN (#msg-165687423).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today